Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
The Mintz Hatch-Waxman litigation group helps research-driven drug companies protect their hard-earned patent rights covering their innovative drug products and therapies. Our deep experience in patent litigation and exceptional technical knowledge and training help us fend off generic manufacturers seeking to prematurely enter the market through Abbreviated New Drug Application filings. Most recently, our team won a complete victory at the U.S. Court of Appeals for the Federal Circuit for our client upholding an earlier victory in Federal District Court in Hatch-Waxman litigation.
We recognize that each litigation is different, and we put the time and resources into ensuring that each case is handled with the utmost attention to details. Whether a single generic has filed an ANDA or a dozen have, clients know that we will bring an efficiently staffed and experienced team to bear on their behalf. Working in support of the litigators who develop strategies in pursuit of your rights are numerous professionals in our practice with PhDs in fields valuable to the pharmaceutical industry including Biochemistry, Chemistry, Chemical Biology, and Organic Chemistry.